GI
RXRX icon

GAMMA Investing’s Recursion Pharmaceuticals RXRX Stock Holding History

GAMMA Investing’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.55K Sell
422
-312
-43% -$1.04K ﹤0.01% 3772
2026
Q1 		$2.25K Sell
734
-939
-56% -$3.63K ﹤0.01% 3636
2025
Q4 		$6.84K Buy
1,673
+1,422
+567% +$7.04K ﹤0.01% 3140
2025
Q3 		$1.23K Buy
251
+193
+333% +$1.01K ﹤0.01% 3571
2025
Q2 		$293 Sell
58
-7,166
-99% -$35.2K ﹤0.01% 3700
2025
Q1 		$38.2K Buy
7,224
+2,026
+39% +$14.8K ﹤0.01% 1984
2024
Q4 		$35.1K Buy
5,198
+4,948
+1,979% +$33.3K ﹤0.01% 1934
2024
Q3 		$1.65K Sell
250
-6,166
-96% -$44.2K ﹤0.01% 3126
2024
Q2 		$48.1K Buy
6,416
+6,036
+1,588% +$52.6K 0.01% 1218
2024
Q1 		$3.79K Buy
380
+130
+52% +$1.45K ﹤0.01% 2524
2023
Q4 		$2.35K Buy
+250
New +$1.78K ﹤0.01% 2528

Other funds holding RXRX

Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
1WA
180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return
SFS
Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return
PL
Plancorp LLC Saint Louis, Missouri $4.1B AUM 25.19% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
AWM
Accel Wealth Management Waverly, Iowa $444M AUM 31.14% 1-Year Est. Return
NWMG
National Wealth Management Group Cincinnati, Ohio $323M AUM 39.23% 1-Year Est. Return
WPC
Wedmont Private Capital West Chester, Pennsylvania $3.65B AUM 26.64% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
ICP
Interchange Capital Partners Pittsburgh, Pennsylvania $532M AUM 26.57% 1-Year Est. Return

GAMMA Investing's RXRX Position: Q2 2026 in Review

GAMMA Investing reduced its Recursion Pharmaceuticals (RXRX) stake by 43% in Q2 2026, selling an estimated $1.04K and leaving 422 shares worth $1.55K. The position accounts for ﹤0.01% of the portfolio, ranked #3772.

GAMMA Investing first reported a position in RXRX in Q4 2023 and has held it in 11 quarters since. The position peaked at $48.1K in Q2 2024. 28 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • GAMMA Investing held 422 shares of Recursion Pharmaceuticals worth $1.55K as of Q2 2026.
  • GAMMA Investing sold 312 Recursion Pharmaceuticals shares in Q2 2026, an estimated $1.04K.
  • Recursion Pharmaceuticals made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3772 holding.
  • GAMMA Investing first reported a position in Recursion Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • GAMMA Investing's Recursion Pharmaceuticals position peaked at $48.1K in Q2 2024.
  • 28 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.